Platelet concentrates (PC) used in tissue regeneration, such as Platelet-rich plasma (PRP) and platelet-rich fibrin (PRF), are typically prepared from patients’ blood at the point of care and used immediately in clinical settings. As a result, the benefits of this therapy can be summed up as increased safety, cost-effectiveness, economic efficiency, and a simple preparation protocol. Furthermore, with the exception of one country, to our knowledge, most countries and regions do not require special regulatory approval for this therapeutic region.
To break this cycle and revitalize PC research and therapy, we must return to the beginning and reconsider how PC acts on injured tissue to facilitate tissue regeneration in collaboration with other systems, such as the immune system. At the very least, it is clear that PC does not upregulate the inherent regenerative potential on their own.
Given this situation, we hope to provide a platform for this research topic where unique ideas and exciting research outcomes can be easily and actively exchanged. Furthermore, challenging research on topics such as, but not limited to, possible causes for varying clinical outcomes and medical technologies for diagnosis and quality assurance to overcome weaknesses is encouraged. This opportunity, we believe, will lead to more predictable PC therapy.
Platelet concentrates (PC) used in tissue regeneration, such as Platelet-rich plasma (PRP) and platelet-rich fibrin (PRF), are typically prepared from patients’ blood at the point of care and used immediately in clinical settings. As a result, the benefits of this therapy can be summed up as increased safety, cost-effectiveness, economic efficiency, and a simple preparation protocol. Furthermore, with the exception of one country, to our knowledge, most countries and regions do not require special regulatory approval for this therapeutic region.
To break this cycle and revitalize PC research and therapy, we must return to the beginning and reconsider how PC acts on injured tissue to facilitate tissue regeneration in collaboration with other systems, such as the immune system. At the very least, it is clear that PC does not upregulate the inherent regenerative potential on their own.
Given this situation, we hope to provide a platform for this research topic where unique ideas and exciting research outcomes can be easily and actively exchanged. Furthermore, challenging research on topics such as, but not limited to, possible causes for varying clinical outcomes and medical technologies for diagnosis and quality assurance to overcome weaknesses is encouraged. This opportunity, we believe, will lead to more predictable PC therapy.
